Andere Sprachen Altamira Therapeutics Ltd.

Aktien

A2PJN3

BMG0360L1349

CYTO

Schlusskurs Nasdaq Andere Börsenplätze 00:00:00 13.05.2024			% 5 Tage	% 1. Jan.
1,44 ^USD	-0,69 %		-8,86 %	-58,62 %

01.05.	Altamira Therapeutics Ltd. meldet die Einreichung einer vorläufigen Patentanmeldung für OligoPhore-Nanopartikel mit siRNA, die auf das Protein p65 abzielt, zur Behandlung von Krebs und Entzündungen	CI
24.04.	Altamira Therapeutics Ltd. gibt die Veröffentlichung der positiven Ergebnisse der Bentrio-Studie bei saisonaler allergischer Rhinitis in einer renommierten Fachzeitschrift bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01.05.
Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01.05.
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24.04.
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24.04.
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K	16.04.
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	10.04.
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	10.04.
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	04.04.
Sector Update: Health Care Stocks Decline Late Afternoon	25.03.
Top Midday Gainers	25.03.
Sector Update: Health Care Stocks Softer in Afternoon Trading	25.03.
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	25.03.
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25.03.
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25.03.
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	07.02.
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	07.02.
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise	24.01.
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	24.01.
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	24.01.
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Altamira Therapeutics Ltd.

Aktien

A2PJN3

BMG0360L1349

CYTO

Andere Sprachen

Filter